Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash & Current Investments (2016 - 2025)

VYNE Therapeutics' Cash & Current Investments history spans 10 years, with the latest figure at $29.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 52.84% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $29.0 million, down 52.84%, while the annual FY2025 figure was $29.0 million, 52.84% down from the prior year.
  • Cash & Current Investments reached $29.0 million in Q4 2025 per VYNE's latest filing, down from $39.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $119.5 million in Q1 2021 to a low of $67000.0 in Q4 2022.
  • Average Cash & Current Investments over 5 years is $50.7 million, with a median of $50.3 million recorded in 2025.
  • Peak YoY movement for Cash & Current Investments: crashed 88.93% in 2022, then soared 139083.58% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $605000.0 in 2021, then plummeted by 88.93% to $67000.0 in 2022, then skyrocketed by 139083.58% to $93.3 million in 2023, then plummeted by 34.03% to $61.5 million in 2024, then tumbled by 52.84% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Cash & Current Investments are $29.0 million (Q4 2025), $39.6 million (Q2 2025), and $50.3 million (Q1 2025).